A "gene silencer" (technically known as small interfering RNA, or siRNA), locally delivered by nanoparticles embedded in an ...

Doctors Studio by Forum Health, LLC today announced pilot findings indicating that intraprostatic ozone therapy was ...

The molecular understanding of brain tumors has undergone a profound transformation in recent years. Advances in genomics, ...

One of the persistent challenges in precision oncology is the fact that most advanced cancers are complex and highly individualized. A recent ...

Key market opportunities include leveraging molecular switches for targeted drug delivery systems and therapies in oncology, autoimmune, inflammatory, and neurological disorders. Innovations in ...

Molecular response to therapy in early-stage PV patients correlates with improved event-free survival outcomes. Ropeginterferon alfa-2b significantly reduces JAK2V617F variant allele frequency, ...

4D Molecular Therapeutics trades below its cash balance, offering significant upside as its late-stage gene therapy programs advance. FDMT's lead asset, 4D-150, targets wet AMD and DME, with Phase 3 ...

NEW YORK, Aug. 26, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to ...

Recombinant immunotoxins represent a sophisticated class of biotherapeutics that combine the targeting specificity of antibody fragments with the potent cytotoxic effects of bacterial or plant toxins.

4D Molecular Therapeutics' lead candidate, 4D-150, aims to provide a one-time gene therapy for Wet-AMD, showing promising but mixed Phase 2 data. Despite setbacks, 4D-150's potential for less frequent ...